Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC

Launched by DANISH LUNG CANCER GROUP · Nov 14, 2018

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment called heterogeneously hypofractionated radiotherapy for patients with locally advanced non-small cell lung cancer (NSCLC) who cannot undergo the standard high-dose treatment. This trial is particularly important for those whose tumors may affect healthy tissue too much or for patients who are not healthy enough to withstand the intense seven-week treatment schedule typically used. By studying this new approach, the researchers hope to find a safer and effective option for these patients.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of locally advanced and inoperable NSCLC. They should also be able to complete the study procedures and follow-ups. Participants can expect to receive a different type of radiation therapy that might help manage their cancer while minimizing side effects. It's essential for participants to understand that they must meet specific criteria, such as not having had previous radiation to the chest area or uncontrolled cancer spread, to be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically or cytological confirmed locally advanced, inoperable NSCLC.
• • Age ≥18 years.
• • Signed informed consent.
• • Performance status 0-2.
• • Able to comply with study and follow-up procedures.
• • Fertile women must have a negative pregnancy test. Fertile men and women must use effective contraception. Fertile women included in the study must use the pill, spiral, depot injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch for the duration of study treatment and one month thereafter.
• Exclusion Criteria:
• • Prior radiotherapy to the thorax, unless there is no significant overlap of current treatment volumes with previous treatment fields.
• • Dose plan conforming to protocol planning criteria not possible.
• • Uncontrolled metastatic disease.
• • Other active malignant disease.